Full Text View
Tabular View
No Study Results Posted
Related Studies
Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer
This study has been completed.
Study NCT00630695   Information provided by University Hospital, Limoges

First Received on February 27, 2008.   Last Updated on January 13, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphocele
Additional conditions recognized in this trial
Breast Neoplasms
More general conditions related to this trial
Breast Diseases
Cysts
Lymphatic Diseases
Neoplasms
Neoplasms by Site
Skin Diseases
Interventions listed in this trial
Lanreotide LP 90
Placebo lanreotide
Additional drug interventions recognized in this trial
Angiopeptin
Lanreotide
Somatostatin
More general drug interventions related to this trial
Antineoplastic Agents
Cardiovascular Agents
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
University Hospital, Limoges
Ipsen


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services